$\mathcal{H}($				
		Application No.	Applicant(s)	
		10/019,284	IZUI ET AL.	
	Notice of Allowability	Examiner	Art Unit	
	·	Elizabeth Slobodyansky, PhD	1652	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.				
1. This communication is responsive to <u>RCE request 14 January 2005</u> .				
2. The allowed claim(s) is/are <u>1-4 and 7</u> .				
3. The drawings filed on <u>02 January 2002</u> are accepted by the Examiner.				
<ul> <li>4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a)  All b)  Some* c) None of the:  1.  Certified copies of the priority documents have been received.  2.  Certified copies of the priority documents have been received in Application No  3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:</li> <li>Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.</li> </ul>				
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.				
<ul> <li>6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.</li> <li>(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached</li> <li>1) hereto or 2) to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date</li> </ul>				
j.	identifying indicla such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).			
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.				
1. ☐ 2. ☐ 3. ☒ 4. ☐	chment(s)  Notice of References Cited (PTO-892)  Notice of Draftperson's Patent Drawing Review (PTO-948)  Information Disclosure Statements (PTO-1449 or PTO/SB/O Paper No./Mail Date 1/14/05; 1/24/05  Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. Interview Summary Paper No./Mail Da 08), 7. Examiner's Amendo	te	

Application/Control Number: 10/019,284

Art Unit: 1652

## **DETAILED ACTION**

## Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on January 14, 2005 has been entered.

Amendment under 37 CFR 1.312 filed November 16, 2004 replacing the Sequence Listing with a substitute Sequence Listing has been entered.

Claims 1-4 and 7 are pending and allowed.

## **REASONS FOR ALLOWANCE**

The following is an examiner's statement of reasons for allowance:

The following is a slightly reworded version of the reasons for allowance given in the Office action mailed October 14, 2004.

Thorough searches of the prior art revealed no previous teaching or suggestion of a) a protein having the activity of sucrose binding enzyme II of the phosphotransferase system from *Brevibacterium lactofermentum* (sucrose PTS enzyme II) or b) a protein having the amino acid sequence of SEQ ID NO:2 and having the activity of sucrose binding enzyme II of the phosphotransferase system from *Brevibacterium lactofermentum* (sucrose PTS enzyme II) or any

Art Unit: 1652

other activity and a DNA encoding thereof. The disruption of the sucrose PTS enzyme II gene results in the loss of ability of the strain containing the disrupted gene to grow on sucrose (page 26, Table 3).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth Slobodyansky, PhD whose telephone number is 571-272-0941. The examiner can normally be reached on M-F 10:00 - 6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, PhD can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Elizabeth Slobodyansky, PhD

E. Stoboolypreestry

Primary Examiner
Art Unit 1652

February 25, 2005